Human Anti-PCSK9 scFv-Fc Chimera (VS-0325-FY208) (CAT#: VS-0325-FY208)

• Immunogen
• Recombinant human PCSK9 protein.

• Host Species
• Human

• Type
• Human IgG1, scFv-Fc

• Specificity
• Human PCSK9

• Species Reactivity
• Human

• Applications
• Western Blot, Blocking

• Related Disease
• Cardiovascular disease, hypercholesterolemia

• Purity
• >95% as determined by SDS-PAGE

• Concentration
• Please refer to the vial label for the specific concentration.

• Storage
• Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

• Shipping
• Ice packs

• Alternative Names
• Proprotein Convertase Subtilisin/Kexin Type 9; Subtilisin/Kexin-Like Protease PC9; NARC-1; NARC1; PC9; Convertase Subtilisin/Kexin Type 9 Preproprotein; Hypercholesterolemia, Autosomal Dominant 3; Neural Apoptosis Regulated Convertase 1; Neural Apoptosis-Regulated Convertase 1

• Gene ID
• 255738

• UniProt ID
• Q8NBP7

• Long Name
• Proprotein Convertase Subtilisin/Kexin Type 9

• Sequence Similarities
• Belongs to the peptidase S8 family.

• Cellular Localization
• Cytoplasm; Endoplasmic reticulum; Endosome; Golgi apparatus; Lysosome; Secreted

• Post Translation Modifications
• Cleavage by furin and PCSK5 generates a truncated inactive protein that is unable to induce LDLR degradation.
  Undergoes autocatalytic cleavage in the endoplasmic reticulum to release the propeptide from the N-terminus and the cleavage of the propeptide is strictly required for its maturation and activation. The cleaved propeptide however remains associated with the catalytic domain through non-covalent interactions, preventing potential substrates from accessing its active site. As a result, it is secreted from cells as a propeptide-containing, enzymatically inactive protein.
  Phosphorylation protects the propeptide against proteolysis.

• Protein Refseq
• NP_777596.2

• Function
• Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments (PubMed:18039658).
  Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation (PubMed:18799458, PubMed:17461796, PubMed:18197702, PubMed:22074827).
  Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway (PubMed:18660751).
  Inhibits epithelial Na+ channel (ENaC)-mediated Na+ absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways.

Isotype Control

• MOB-200CQ
• Human IgG Fc Isotype Control Antibody

Secondary Antibody

• 2ND-029CQ
• Goat Anti-Human IgG Fc Antibody

Select a product category from the dropdown menu below to view related products.